Santosh Menon, MD
Advanced Heart Failure and Transplant Cardiology · Cincinnati, OHNPI 1134185481
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $23,700 of the $30,488 with a category attached, or 77.7%. Novartis accounts for 82.1% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2019 at $19,111 and has fallen 99.3% since, to $126 in 2025.
Across 190 payments — averaging $160.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$25K
- Abbott$3K
- AstraZeneca$476
- Boehringer Ingelheim$354
- Johnson & Johnson$295
- Amarin Pharma, Inc.$214
- plus $1K from 17 others
Across 2 payments — averaging $225.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$450
What the payments were for
- Consulting fees$1,6005%
- Speaking & faculty fees$23,70078%
- Travel & lodging$320%
- Food & beverage$5,04917%
- Education$110%
- Gifts$950%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 73 | $25,038 |
| Abbott | 15 | $2,687 |
| AstraZeneca | 9 | $476 |
| Boehringer Ingelheim | 14 | $354 |
| Johnson & Johnson | 24 | $295 |
| Amarin Pharma, Inc. | 8 | $214 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $179 |
| Medtronic | 4 | $160 |
| Amgen | 8 | $152 |
| Sanofi-aventis U.S. LLC | 3 | $143 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $130 |
| Esperion Therapeutics, Inc. | 1 | $114 |
| Boston Scientific | 3 | $106 |
| Tosoh Bioscience, Inc. | 1 | $95 |
| Regeneron Healthcare Solutions, Inc. | 4 | $65 |
| Philips North America LLC | 1 | $59 |
| E.r. Squibb & Sons, L.L.C. | 4 | $46 |
| Pfizer | 3 | $43 |
| Merck | 2 | $36 |
| Edwards Lifesciences | 2 | $35 |
| Scpharmaceuticals Inc. | 1 | $27 |
| Cvrx, Inc. | 1 | $18 |
| Bardy Diagnostics, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ENTRESTO$24,405
- HeartMate Touch$1,600
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$733
- FARXIGA$373
- CARDIOMEMS$229
- Vascepa$123
- PRALUENT$121
- JARDIANCE$114
- NEXLETOL$114
- LifeVest$100
How this compares
$30,488 in reported general payments places this provider in the 80th percentile of 62 advanced heart failure and transplant cardiology providers in Ohio.
See all advanced heart failure and transplant cardiology providers in Ohio →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 556 | $590,493 |
| EntrestoSacubitril/Valsartan | 465 | $499,408 |
| JardianceEmpagliflozin | 199 | $238,123 |
| XareltoRivaroxaban | 176 | $157,318 |
| FarxigaDapagliflozin Propanediol | 91 | $94,869 |
| Repatha SureclickEvolocumab | 98 | $60,273 |
| Repatha PushtronexEvolocumab | 24 | $15,625 |
| Praluent PenAlirocumab | 15 | $7,068 |
| Repatha SyringeEvolocumab | 13 | $6,907 |
| BrilintaTicagrelor | 11 | $6,453 |
| Metoprolol Succinate | 387 | $4,732 |
| Ezetimibe | 158 | $4,035 |
| Amiodarone Hcl | 123 | $3,298 |
| Atorvastatin Calcium | 338 | $3,284 |
| Bisoprolol Fumarate | 176 | $3,098 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $43 | $590,493556 claims |
| NovartisEntresto | $25,038 | $499,408465 claims |
| Boehringer IngelheimJardiance | $354 | $238,123199 claims |
| Johnson & JohnsonXarelto | $295 | $157,318176 claims |
| AstraZenecaFarxiga, Brilinta | $476 | $101,322102 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 62 advanced heart failure and transplant cardiology providers in Ohio.
Other advanced heart failure and transplant cardiology in Cincinnati
- Eugene ChungCincinnati$297K
- Ankit BhatiaCincinnati$141K
- Rachel GarciaCincinnati$104K
- Sateesh KesariCincinnati$101K
- Sitaramesh EmaniCincinnati$87K
- Gregory EgnaczykCincinnati$62K
- Umama GorsiCincinnati$20K
- Stephanie DunlapCincinnati$9K
- Mahyar PourriahiCincinnati$8K
- Juliane ViereckeCincinnati$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.